Statin Therapy in Patients with Severe Kidney Failure

Introduction to Statin Therapy

• Pravastatin is metabolized via non-CYP pathways, while atorvastatin undergoes CYP3A4 metabolism, reducing drug interaction potential in patients with kidney failure 1
• The American Heart Association and American College of Cardiology recommend moderate-intensity statin therapy for patients with non-dialysis CKD who are 40-75 years of age with LDL-C 70-189 mg/dL and at elevated ASCVD risk 3

Patient Assessment and Monitoring

• For patients with eGFR <30 ml/min/1.73m² (severe kidney failure), pravastatin is preferred, and renal function should be monitored regularly after initiation 1
• The American College of Cardiology recommends assessing baseline renal function and considering cardiovascular risk profile when initiating statin therapy 3

Medication Management

• Pravastatin has fewer drug interactions due to its non-CYP metabolism, and medication review should include checking for potential drug interactions with current medications 1
• The American College of Cardiology recommends starting with lower doses in severe kidney disease and considering dosing adjustments based on renal function 3

Guideline Recommendations

• The American Heart Association and American College of Cardiology recommend against initiating statin therapy in adults with advanced kidney disease requiring dialysis treatment, but it may be reasonable to continue statin therapy in those already on it 3
• The American Journal of Kidney Diseases suggests that pravastatin demonstrated effectiveness for secondary prevention of cardiovascular events in persons with mild chronic kidney insufficiency 2

Comprehensive CKD Management

• Comprehensive CKD management should include blood pressure control, ACEi/ARB therapy when appropriate, and consideration of SGLT2 inhibitors for patients with diabetes, in addition to choosing the appropriate statin 4